Last reviewed 2026-05-14 · How we verify

Matching placebo to omarigliptin

Matching placebo to omarigliptin is a DPP-4 inhibitor Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Type 2 diabetes mellitus.

Omarigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to stimulate insulin secretion and reduce glucagon in response to elevated blood glucose.

Omarigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to stimulate insulin secretion and reduce glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

DPP-4 inhibitors work by blocking the enzyme that degrades glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their action. This leads to glucose-dependent stimulation of insulin secretion and suppression of glucagon secretion, resulting in improved glycemic control in type 2 diabetes. Omarigliptin is a long-acting DPP-4 inhibitor designed for once-weekly dosing.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Hypoglycemia
• Nasopharyngitis
• Upper respiratory tract infection
• Headache

Key clinical trials

• A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (PHASE3)
• Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) (PHASE3)
• A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (PHASE3)
• Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
• A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028) (PHASE3)
• A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006) (PHASE2)
• A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027) (PHASE3)
• A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Matching placebo to omarigliptin CI brief — competitive landscape report
• Matching placebo to omarigliptin updates RSS · CI watch RSS
• Merck Sharp & Dohme LLC portfolio CI

Frequently asked questions about Matching placebo to omarigliptin

Related

• Drug class: All DPP-4 inhibitor drugs
• Target: All drugs targeting Dipeptidyl peptidase-4 (DPP-4)
• Manufacturer: Merck Sharp & Dohme LLC — full pipeline
• Therapeutic area: All drugs in Diabetes
• Indication: Drugs for Type 2 diabetes mellitus
• Compare: Matching placebo to omarigliptin vs similar drugs
• Pricing: Matching placebo to omarigliptin cost, discount & access